Australia's largest stock trading and investment forum Australia's #1 stock forum

ESN

0.00%

1.6¢ entellect limited

Forgot to add - Maybe a revolving line of credit (convertible...

First 9 Last

Share
Profile

Follow
MeToo

7,639 Posts.

483

06/02/15

12:46

Post #: 14709918
Share

Originally posted by MeToo ↑

The notes are at the discretion of the holder and the options may not be converted, that's why I used the word "potential"
If the remaining notes expire at the end of Feb. (I cannot be bothered checking) they will have to be repaid with interest or converted by the holder at his/her discretion, either way it's a lot $ to come up with or a lot of shares to be issued.
The holders may have no choice but to convert if ESN don't have or cannot get the funds to repay them.

If the 200m options are converted it will put $25k per 25m into the kitty that could go towards note repayment, fees or other working capital then add 200m shares to the register.
These shares (converted options or converted notes)
could then be put on market and sold at >=$00.001 to break even or return a quick profit, assuming there are any buyers. The same can apply for the notes, if converted.

Maybe a positive spin ann. is about to be released?

Committed revenue, surely if the committed revenue has been received there should/would be an ann. (it would be a significant mile stone?)
Seeing they announced "First significant (committed) revenue (due in Jan-2015)" in early December one would expect a follow up ann. in Jan. to inform the market of delays or progress?

Is the committed revenue recurring or one off?
Has the government hand out stopped?

Expand

Forgot to add - Maybe a revolving line of credit (convertible notes) is the order of the day? New ones to repay the old ones and their interest?

ESN Price at posting: 0.1¢ Sentiment: None Disclosure: Not Held
Upvote

0 Great analysis

Reply

Top Stories

NWC

New World Resources inks complete PFS for Antler Copper Project in Arizona, USA

VMM

Virdis Mining flags breakthrough with 76% neodymium and praseodymium recoveries

CTT

Cettire shares jump on FY24 revenue growth up 80% vs pcp – but stock still badly bruised

ATH

Trial for Alterity's neurodegenerative drug ATH434 shows reduced disability

LRL

Labyrinth shares rocket by 219% on news of Comet Vale and Vivien gold project acquisitions